the aid library

Filter

929

Geographical, landscape and host associations of Trypanosoma cruzi DTUs and lineages

Izeta-Alberdi, A.; Ibarra-Cerdena, C.; Moo-llanes, D.; Ramsey,J. BMC Part of Springer Nature (2016) CC

Trypanosoma cruzi is the etiological agent of Chagas disease (CD), considered one of the most important parasitic infections in Latin America. Between 25 and 90 million humans are at infection risk via at least one of multiple infection mechanisms. Under natural conditions, the principal transmissio ... more

Target product profile for a point-of-care diagnostic test for dermal leishmaniases - Control of Neglected Tropical Diseases

World Health Organization World Health Organization WHO (2022) C_WHO

Localized cutaneous leishmaniasis and its evolving forms (diffuse cutaneous leishmaniasis, mucosal leishmaniasis and cutaneous leishmaniasis recidivans), together with the sequela of visceral leishmaniasis (post-kala-azar dermal leishmaniasis), account for about one million cases of dermal leishmani ... more

Leptospirosis in sugarcane plantation and fishing communities in Kagera northwestern Tanzania

Mgode, G.; Japhary, M.; Mhamphi, G. PLoS Neglected Tropical diseases (2019) CC

Leptospirosis is a bacterial zoonotic disease of worldwide importance, though relatively neglected in many African countries including sub Saharan Africa that is among areas with high burden of this disease. The disease is often mistaken for other febrile illnesses such as dengue, malaria, rickettsi ... more

Diagnostic test for lymphatic filariasis to support decisions for stopping triple-therapy mass drug administration: target product profile

World Health Organization World Health Organization WHO (2021) C_WHO

TARGET PRODUCT PROFILE

Zoonotic diseases of public health importance

National Institue of communicable Diseases, India (1998) C1

Diagnostic target product profiles for monitoring, evaluation and surveillance of schistosomiasis control programmes

World Health Organization World Health Organization WHO (2021) C_WHO

Health ministries currently lack effective tools for monitoring and evaluation of schistosomiasis control programmes. Egg detection can be used, but the cost, challenges of obtaining samples, and the need for trained personnel and equipment limit the frequency of monitoring. The purpose of this TPP ... more

Inter-Agency Reproductive Health Kits 6th Edition - Manual

Inter-Agency Working Group on Reproductive Health in Crisis IAWG and UNFPA (2021) C1

Global vaccine safety blueprint 2.0 (GVSB2.0) 2021-2023

World Health Organization WHO (2022) C_WHO

Basic Epidemiology

Bonita, R.; R.Beaglehole, and T. Kjellström World Health Organization WHO (2006) C_WHO

2nd edition

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for ... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Interim National Guidelines for Monkeypox Outbreak Response

Federal Ministry of Health - Nigeria Centre for Disease Contro (2017) C2

This document provides information and recommendations for action, based on the current available knowledge around monkeypox. It is a first draft which will be updated in light of evolving evidence and additional information as they become available.

Guidelines for the Treatment of Chronic Hepatitis B and C Viral Infections in Kenya
recommended

Prof. G. N. Lule, Dr. B. Nyawira Gastroenterology Society of Kenya , Republic of Keny (2015) C1

The ACT-Accelerator: Two years of impact

World Health Organization WHO (2022) C_WHO

The two-year impact report for the Access to COVID-19 Tools (ACT) Accelerator details impact, case studies and timelines of key milestones for the Diagnostics, Therapeutics and Vaccines pillars, as well as the Health Systems and Response Connector.

Leveraging Vaccines to Reduce Antibiotic Use and Prevent Antimicrobial Resistance

World Health Organization WHO (2021) C_WHO

An Action Framework and annexe to Immunization Agenda 2030 (Draft version) 27 January 2021

Health system considerations: when influenza meets COVID-19: preparedness and response measures when COVID-19, influenza and acute respiratory infections coincide in the WHO European Region

World Health Organization WHO, Regional Office of Europe (2020) C_WHO

revised version December 2020

WHO Drug Information - Volume 36, No. 4

World Health Organisation (WHO) (2023) C_WHO

Pharmaceutical News Evaluation of Saccharide Content of the WHO 2nd International Standard for Haemophilus Influenzae Polysaccharide Polyribosyl Ribitol Phosphate (PRP) by HPAECPAD Analysis Following Acid Hydrolysis Consultation Documents Lamivudine and tenofovir disoproxil fumarate tablets (lami ... more

Guideline for Hand Hygiene in Health-Care Settings

Centers for Disease Control and Prevention CDC (2002) C_CDC

Recommendations of the Healthcare Infection Control Practices Advisory Committee and the HICPAC/SHEA/APIC/IDSA Hand Hygiene Task Force

Zika Virus Research Agenda - October 2016

World Health Organization WHO (2016) C_WHO

Management of Tuberculosis: A Guide to the Essentials of Good Clinical Practice
recommended

International Union Against Tuberculosis and Lung Disease (2019) C1

The 7th edition of the Orange Guide provides practical guidance to health workers on the front line of TB control. It includes sections on HIV, MDR-TB and a review of the recommended treatment regimens